Clinical Trial Update: A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia [Phase 3]

View source ↗

Summary

Phase 3 study of KRN23 in pediatric patients with X-linked hypophosphatemic rickets/osteomalacia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Hypophosphatemic Rickets Osteomalacia

Drugs mentioned

• KRN23 (burosumab)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: X-linked Hypophosphatemic Rickets/Osteomalacia | Phase 3 | Status: COMPLETED